Seres Therapeutics

Seres Therapeutics (NASDAQ: MCRB) is a publicly traded leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company raised a $134M IPO in 2015, just three years after it launched.


Company Profile

Seres Therapeutics Logo

Flagship Partners:

  • Noubar Afeyan, Founder & CEO
  • David Berry, General Partner